Common Contracts

5 similar Underwriting Agreement contracts by Adma Biologics, Inc., Halozyme Therapeutics Inc, Parallel Petroleum Corp, others

Scilex Holding Company 5,882,353 Shares of Common Stock (par value $0.0001 per share) (the “Common Stock”) 5,882,353 Warrants to Purchase 5,882,353 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • March 5th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York

Scilex Holding Company, a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 5,882,353 shares of its common stock, par value $0.0001 per share (the “Shares”, and the 5,882,353 Shares to be sold by the Company are called the “Firm Shares”) and (ii) an aggregate of warrants to purchase an aggregate of 5,882,353 shares of Common Stock, in the form set forth in Schedule B hereto, to purchase shares of Common Stock (the “Firm Warrants”). The Firm Shares, together with the Firm Warrants, are herein called the “Firm Securities.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 882,352 shares of Common Stock (the “Optional Shares”) and/or Common Warrants to purchase up to an aggregate of 882,352 shares of Common Stock (the “Optional Warrants,” and together with the Optional Shares, the “Optional Securiti

23,500,000 Shares ADMA BIOLOGICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT
Underwriting Agreement • February 7th, 2020 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • New York

The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and Jefferies LLC (“Jefferies”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with ADMA Biologics, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including Morgan Stanley and Jefferies (the “Underwriters”), of shares (the “Shares”) of common stock, $0.0001 par value per share, of the Company (the “Common Stock”).

275,000,000 Aggregate Principal Amount of 4.00% Fixed-to-Floating Rate Subordinated Notes due 2029 Sterling Bancorp UNDERWRITING AGREEMENT
Underwriting Agreement • December 16th, 2019 • Sterling Bancorp • National commercial banks • New York
6,150,000 Shares HALOZYME THERAPEUTICS, INC. Common Stock ($.001 par value) UNDERWRITING AGREEMENT
Underwriting Agreement • June 23rd, 2009 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • New York

Introductory. Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Jefferies & Company, Inc. as sole underwriter (“Jefferies” or the “Underwriter”) an aggregate of 6,150,000 shares (a “Share” and, collectively, the “Shares”) of common stock, $0.001 par value per share (the “Common Stock”) of the Company.

Parallel Petroleum Corporation Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 11th, 2006 • Parallel Petroleum Corp • Crude petroleum & natural gas • New York

Introductory. Parallel Petroleum Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to Jefferies & Company, Inc., as sole underwriter (the “Underwriter”), an aggregate of 2,500,000 shares of its common stock, par value $.01 per share (the “Shares”). The 2,500,000 Shares to be sold by the Company are collectively called the “Offered Shares.”